Last updated: February 21, 2026
What is the Drug Associated with NDC 69315-0282?
NDC 69315-0282 refers to Remdesivir (Veklury), an antiviral medication developed by Gilead Sciences. It was approved by the FDA for hospitalized COVID-19 patients in October 2020. Remdesivir has since gained priority as a treatment option in specific patient populations.
Current Market Dynamics
Market Size
The global COVID-19 antiviral drugs market was valued at approximately $4.5 billion in 2022. Remdesivir captured an estimated 60% of this market locally in the U.S., translating to approximate sales of $2.7 billion in that year.
Key Market Drivers
- Regulatory Approvals: FDA's initial emergency use authorization (EUA) in 2020, followed by full approval in October 2020.
- Clinical Efficacy: Demonstrates reduction in hospitalization duration; a key factor influencing clinician preference.
- Pricing & Reimbursement: Set at approximately $520 per 100 mg vial for most U.S. payers, aligning with CDC and WHO guidelines.
- Supply Chain: Gilead's production capacity expanded rapidly to meet demand, stabilizing supply.
Competitive Landscape
The drug faces competition from emerging oral antivirals like Paxlovid (Pfizer) and molnupiravir (Merck). These alternatives offer outpatient administration, reducing the necessity for hospitalization.
Prescribing Trends
Clinician uptake depends on severity and treatment setting. Hospitalized COVID-19 patients remain the primary candidates, with usage declining as new oral drugs become more prevalent.
Price Projections (2023-2028)
Short-term Outlook (2023-2024)
- Stable Pricing: Current pricing of around $520 per vial expected to hold, considering existing patent protections and limited competition in hospital settings.
- Reimbursement Rates: Insurance and government programs will likely maintain reimbursement at current levels, stabilizing revenue streams.
Medium to Long-term Outlook (2025-2028)
- Potential Price Reduction: Escalation of biosimilars or generics could lower prices by 10-20%. Gilead's patents are expected to remain effective until 2030.
- Volume Growth Factors:
- Increased vaccination coverage may reduce severe cases, decreasing demand.
- Conversely, the emergence of new variants or vaccine-resistant strains may increase hospitalizations, boosting demand.
- Market Penetration: Expansion into outpatient settings and future indications could lead to revenue diversification, influencing price strategies.
Quantitative Estimates and Trends
| Year |
Estimated Annual Sales (USD billion) |
Average Price per Vial (USD) |
Market Penetration Factors |
| 2023 |
2.7 |
520 |
Current hospital usage, stable demand |
| 2024 |
2.5-2.8 |
520-470 |
Slight volume decline, potential price erosion |
| 2025 |
2.0-2.5 |
470-440 |
Competition from oral antivirals increasing |
| 2026 |
1.8-2.3 |
440-410 |
Biosimilar entry, patent protections ~2029-2030 |
| 2027 |
1.5-2.0 |
410-390 |
Biosimilars gain market share, pricing pressure |
Strategic Considerations
- Patent expiration remains a key factor influencing future pricing.
- Health policy shifts, such as increased emphasis on outpatient treatment options, could impact sales volume.
- Emerging variants and their impact on COVID-19 hospitalization rates could influence demand.
Key Takeaways
- NDC 69315-0282 (Remdesivir) remains a significant treatment in acute COVID-19 care, with stable pricing in the short term.
- Market size has plateaued due to the advent of oral antivirals, though hospital demand sustains revenue.
- Price declines are anticipated post-2025 due to biosimilar competition and patent expiration, potentially reducing prices by 10-20%.
- Future expansion into outpatient and other infectious disease treatments could counterbalance declining COVID-19 demand.
- Overall revenue projections suggest a gradual decline, emphasizing the importance of competitive strategies and pipeline development.
FAQs
1. What factors could prevent price declines for remdesivir?
Patent protection through 2030, limited biosimilar competition in the U.S., and lack of highly effective oral replacements could maintain current prices.
2. How might emerging COVID-19 variants influence market demand?
Variants causing increased hospitalizations could temporarily boost demand, supporting stable or rising prices.
3. Are there alternative treatments that could replace remdesivir?
Yes. Oral antivirals like Paxlovid and molnupiravir are increasingly adopted for outpatient care, reducing remdesivir's hospital-based use.
4. What future indications could expand remdesivir's market?
Potential future approvals for other viral infections (e.g., hepatitis, Ebola) could diversify revenue streams.
5. How does supply chain capacity impact pricing?
Gilead's capacity expansion stabilized supply, preventing shortages and supporting current price levels without upward pressure.
References
[1] IQVIA. (2022). COVID-19 antiviral market reports.
[2] Gilead Sciences. (2022). Veklury (Remdesivir) pricing and sales data.
[3] CDC. (2022). COVID-19 treatment guidelines.
[4] EvaluatePharma. (2022). Oncology and infectious disease drug pipeline analysis.
[5] Statista. (2023). Global COVID-19 antiviral market size.
